Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study observed that simvastatin promoted hair regrowth in a mouse model of alopecia areata by reducing inflammatory markers and T cell proliferation, partly through disruption of isoprenoid metabolite production.

This study found that caffeic acid amide derivative, compound 4, effectively inhibited steroid 5α-reductase type 1 in vitro, suggesting potential for development as a treatment for androgenic alopecia.

In this study, researchers found that Derinat, a TRPCs inhibitor, reduced oxidative stress and prolonged the anagen phase of hair growth in mice, supporting its potential as a therapy for androgenetic alopecia by improving clinical outcomes and enhancing quality of life for those affected.

This review discusses the development and potential therapeutic applications of steroid sulfatase inhibitors for hormone-dependent disorders and cognitive dysfunction, reporting no new clinical results.

This study found that in primary cicatricial alopecia, reducing cholesterol production and targeting EMT modulators like PPARγ, AhR, AGTR, and TGFβ with siRNA may help mitigate hair follicle damage by modulating epithelial-mesenchymal transition, suggesting potential therapeutic strategies for slowing PCA progression.

This study found that androgenic steroids, particularly androstenedione and androstanedione, significantly reduced the growth of certain dermatophytes, suggesting hormonal influence on fungal infections in hair follicles.

In laboratory experiments, this study found that the topical prodrug SCD-153, a derivative of 4-methyl itaconate, reduced inflammation-related gene expression and induced significant hair growth in mice, suggesting it as a promising treatment candidate for alopecia areata.

This study suggests that the C-terminal of AHF is crucial for its binding to keratin bundles and modulating the keratin meshwork in hair follicles.

This study found that cilostazol promoted hair growth in human dermal papilla cells and mouse models, suggesting its potential as a therapeutic target for alopecia treatment.

This study concluded that statins do not independently improve alopecia areata, as age confounds their perceived efficacy.

Treatment with oral terbinafine and topical enilconazole was successful in resolving a Trichophyton dermatophytosis outbreak in L'Hoest's monkeys, with complete mycological cure achieved after eight weeks.

This study reported that platelet-rich plasma therapy combined with intralesional triamcinolone acetonide was beneficial for patients with alopecia totalis, helping them reduce reliance on oral immunosuppressants.

In this animal study, atorvastatin co-administered with trastuzumab reversed trastuzumab-induced cognitive impairment (chemo-brain) and improved its anti-cancer efficacy without causing hair loss.

In this study, dutasteride, but not finasteride, reduced high-grade PIN lesions more effectively in C57xFVB TRAMP mice, although both drugs increased the incidence of poorly differentiated prostate cancer.

In this study, researchers formulated a topical gel containing β-sitosterol for alopecia treatment and found it demonstrated good 5 alpha reductase inhibitory activity in vitro, comparable to a commercial product, indicating its potential for further antiandrogenic activity investigation.

This study found that targeting mTORC1 with rapamycin effectively inhibited skin tumor promotion in a mouse model, highlighting a potential target for cancer chemoprevention.

This study evaluated the stability of multiple active ingredients in TrichoSol™ for use in alopecia treatments, finding varying stability durations at room temperature—up to 180 days for some ingredients—supporting its use as a compounding vehicle in personalized therapies.

This study synthesized and evaluated hydroxycinnamate derivatives for their ability to inhibit human SRD5A1, finding that three compounds showed significant inhibitory activity and low cytotoxicity. Compound 10a notably reduced SRD5A1 protein expression in cells, suggesting potential for nonsteroidal treatment of androgen-related conditions.

This study found that botulinum toxin type A may reduce apoptosis in dermal papillary cells induced by dihydrotestosterone through the circ_0135062/miR-506-3p/Bax axis.

This animal study found that YH0618 may alleviate doxorubicin-induced alopecia and affects proteins like keratin and Smad3, suggesting potential therapeutic targets. The researchers analyzed protein expression changes to understand YH0618's effects in treating chemotherapy-related hair loss.

TP0427736 may help treat hair loss by blocking a specific protein and promoting hair growth.

In this study, topical trypsin treatment following depilation in a mouse model induced cell death at the follicular papilla, delaying hair growth and pigmentation.

This study suggests that inhibiting 5α-reductase activity alone, particularly with the type 1 inhibitor MK386, may not effectively reduce sebocyte activity or improve acne.

This research developed new in vitro models for high-throughput screening of drugs that could protect or restore immune privilege in hair follicles, finding that Tofacitinib was effective in preventing inflammation-related marker upregulation, while Tacrolimus and αMSH worked specifically in outer root sheath keratinocytes.

In this study, a combination of terbinafine and mitotane was used to treat a dog with pituitary-dependent hyperadrenocorticism and dermatophytosis, showing regrowth of hair and negative fungal cultures without detectable adverse effects.